At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma ...
Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity ...
The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s ...
New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision ...
Acadia Pharmaceuticals Inc.’s near miss disclosed Sept. 24 in phase II with 5HT2A receptor inverse agonist remlifanserin in ...
A complaint filed in 2023 by Nektar Therapeutics Inc. against former partner Eli Lilly and Co. regarding development of Treg stimulator rezpegaldesleukin (rezpeg) ended this week with the jury ...
In a continuous effort to improve its cardiometabolic franchise, Novo Nordisk A/S entered a deal worth up to €1.165 billion ...
At the International Myeloma Society meeting, Brightpath Biotherapeutics Co. Ltd. presented data for BP-2202, an ...
Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...
Sotio Biotech AS’s SOT-106 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcoma and ...
Xtalpi Inc. has submitted an IND application to the FDA for KQTD-126, a gut-restricted pan-TRK inhibitor designed to treat chronic intestinal pain associated with irritable bowel syndrome and ...
Cellular senescence is commonly associated with aging, but it also plays essential roles during embryonic development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results